Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Platform Trial of BI 754091-Based Combinations in Advanced Solid Tumours
2018-002344-81Phase 2Unknown
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ezabenlimab in Nonhematologic neoplasms, Metastatic solid neoplasm and cancer (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Objective response (OR). Status: unknown.
02
Drugs
ezabenlimab
03
Conditions
Nonhematologic neoplasmsMetastatic solid neoplasmcancer
Beyond the preview
Go deeper on 2018-002344-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002344-81.